(Q24246506)

22 October 2023

L Richeldi

1

L

Richeldi

1 reference

22 October 2023

LM Fabbri

series ordinal

3

author given names

L M

author last names

Fabbri

1 reference

22 October 2023

TJ Lasserson

series ordinal

4

author given names

T J

author last names

Lasserson

1 reference

22 October 2023

PG Gibson

series ordinal

5

author given names

P G

author last names

Gibson

1 reference

Cochrane Database of Systematic Reviews

22 October 2023

publication date

20 July 2005

0 references

published in

0 references

cites work

Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

Is Chlamydia pneumoniae important in asthma? The first controlled trial of therapy leaves the question unanswered

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

The use of macrolide antibiotic substances in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Inhibition of theophylline clearance by troleandomycin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

The effect of troleandomycin on methylprednisolone elimination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid-requiring asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Dose- and time-related effect of troleandomycin on methylprednisolone elimination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Anti-inflammatory effects of macrolide antibiotics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

The macrolides: erythromycin, clarithromycin, and azithromycin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002997.PUB2

7 January 2021

10.1002/14651858.CD002997.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_p5cz2y5mifhhjdko5aworcc7pe

0 references